X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs BIOCON LTD - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA BIOCON LTD AUROBINDO PHARMA/
BIOCON LTD
 
P/E (TTM) x 17.8 36.8 48.4% View Chart
P/BV x 5.8 4.9 118.2% View Chart
Dividend Yield % 0.4 1.5 23.7%  

Financials

 AUROBINDO PHARMA   BIOCON LTD
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-16
BIOCON LTD
Mar-16
AUROBINDO PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,541496 310.8%   
Low Rs582397 146.8%   
Sales per share (Unadj.) Rs237.5174.3 136.3%  
Earnings per share (Unadj.) Rs33.944.8 75.6%  
Cash flow per share (Unadj.) Rs40.656.9 71.3%  
Dividends per share (Unadj.) Rs2.505.00 50.0%  
Dividend yield (eoy) %0.21.1 21.0%  
Book value per share (Unadj.) Rs120.6202.8 59.5%  
Shares outstanding (eoy) m585.17200.00 292.6%   
Bonus/Rights/Conversions PREF--  
Price / Sales ratio x4.52.6 174.6%   
Avg P/E ratio x31.310.0 314.7%  
P/CF ratio (eoy) x26.27.8 333.7%  
Price / Book Value ratio x8.82.2 400.0%  
Dividend payout %7.411.2 66.1%   
Avg Mkt Cap Rs m621,04189,220 696.1%   
No. of employees `00013.34.4 301.0%   
Total wages/salary Rs m15,5086,363 243.7%   
Avg. sales/employee Rs Th10,457.67,894.5 132.5%   
Avg. wages/employee Rs Th1,167.11,441.2 81.0%   
Avg. net profit/employee Rs Th1,491.62,029.7 73.5%   
INCOME DATA
Net Sales Rs m138,96134,854 398.7%  
Other income Rs m1,663845 196.8%   
Total revenues Rs m140,62435,699 393.9%   
Gross profit Rs m32,0568,200 390.9%  
Depreciation Rs m3,9262,423 162.0%   
Interest Rs m2,568102 2,517.3%   
Profit before tax Rs m27,2256,520 417.6%   
Minority Interest Rs m39-744 -5.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m05,754 0.0%   
Tax Rs m7,4442,569 289.8%   
Profit after tax Rs m19,8208,961 221.2%  
Gross profit margin %23.123.5 98.1%  
Effective tax rate %27.339.4 69.4%   
Net profit margin %14.325.7 55.5%  
BALANCE SHEET DATA
Current assets Rs m100,01539,932 250.5%   
Current liabilities Rs m74,75916,276 459.3%   
Net working cap to sales %18.267.9 26.8%  
Current ratio x1.32.5 54.5%  
Inventory Days Days10754 200.5%  
Debtors Days Days11086 127.2%  
Net fixed assets Rs m52,35039,101 133.9%   
Share capital Rs m5851,000 58.5%   
"Free" reserves Rs m67,70738,591 175.4%   
Net worth Rs m70,56740,556 174.0%   
Long term debt Rs m8,47220,724 40.9%   
Total assets Rs m156,99484,816 185.1%  
Interest coverage x11.664.9 17.9%   
Debt to equity ratio x0.10.5 23.5%  
Sales to assets ratio x0.90.4 215.4%   
Return on assets %14.310.7 133.5%  
Return on equity %28.122.1 127.1%  
Return on capital %37.719.0 198.8%  
Exports to sales %51.030.7 166.0%   
Imports to sales %18.820.4 92.5%   
Exports (fob) Rs m70,92710,717 661.8%   
Imports (cif) Rs m26,1937,105 368.7%   
Fx inflow Rs m71,01511,789 602.4%   
Fx outflow Rs m28,7998,393 343.1%   
Net fx Rs m42,2163,396 1,243.1%   
CASH FLOW
From Operations Rs m17,5965,264 334.3%  
From Investments Rs m-13,801-9,540 144.7%  
From Financial Activity Rs m-19810,867 -1.8%  
Net Cashflow Rs m3,5976,591 54.6%  

Share Holding

Indian Promoters % 54.1 40.4 133.9%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 8.0 8.4 94.6%  
FIIs % 27.7 10.7 258.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 19.9 51.3%  
Shareholders   69,601 109,995 63.3%  
Pledged promoter(s) holding % 8.6 0.0 21,400.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   PLETHICO PHARMA  AJANTA PHARMA  UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Strong; Consumer Durables Stocks Drag(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are trading above the dotted line. Except stocks in the consumer durables sector.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 23, 2017 02:34 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS